IRE-1α inhibitors
Compounds which directly inhibit IRE-1α activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response or with regulated IRE1-dependent decay (RIDD) and can be used as single agent...
Gespeichert in:
| Hauptverfasser: | , , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | Patterson John Bruce Wade Warren Stanfield Zubovics Zoltan Yang Yun Toro Andras Wu Zhipeng Zeng Qingping |
| description | Compounds which directly inhibit IRE-1α activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response or with regulated IRE1-dependent decay (RIDD) and can be used as single agents or in combination therapies. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_US9867803B2</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>US9867803B2</sourcerecordid><originalsourceid>FETCH-epo_espacenet_US9867803B23</originalsourceid><addsrcrecordid>eNrjZBDyDHLVNTy3USEzLyMzKbMkv6iYh4E1LTGnOJUXSnMzKLi5hjh76KYW5MenFhckJqfmpZbEhwZbWpiZWxgYOxkZE6EEAMoLH_U</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>IRE-1α inhibitors</title><source>esp@cenet</source><creator>Patterson John Bruce ; Wade Warren Stanfield ; Zubovics Zoltan ; Yang Yun ; Toro Andras ; Wu Zhipeng ; Zeng Qingping</creator><creatorcontrib>Patterson John Bruce ; Wade Warren Stanfield ; Zubovics Zoltan ; Yang Yun ; Toro Andras ; Wu Zhipeng ; Zeng Qingping</creatorcontrib><description>Compounds which directly inhibit IRE-1α activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response or with regulated IRE1-dependent decay (RIDD) and can be used as single agents or in combination therapies.</description><language>eng</language><subject>CHEMISTRY ; HETEROCYCLIC COMPOUNDS ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><creationdate>2018</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20180116&DB=EPODOC&CC=US&NR=9867803B2$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20180116&DB=EPODOC&CC=US&NR=9867803B2$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>Patterson John Bruce</creatorcontrib><creatorcontrib>Wade Warren Stanfield</creatorcontrib><creatorcontrib>Zubovics Zoltan</creatorcontrib><creatorcontrib>Yang Yun</creatorcontrib><creatorcontrib>Toro Andras</creatorcontrib><creatorcontrib>Wu Zhipeng</creatorcontrib><creatorcontrib>Zeng Qingping</creatorcontrib><title>IRE-1α inhibitors</title><description>Compounds which directly inhibit IRE-1α activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response or with regulated IRE1-dependent decay (RIDD) and can be used as single agents or in combination therapies.</description><subject>CHEMISTRY</subject><subject>HETEROCYCLIC COMPOUNDS</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2018</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZBDyDHLVNTy3USEzLyMzKbMkv6iYh4E1LTGnOJUXSnMzKLi5hjh76KYW5MenFhckJqfmpZbEhwZbWpiZWxgYOxkZE6EEAMoLH_U</recordid><startdate>20180116</startdate><enddate>20180116</enddate><creator>Patterson John Bruce</creator><creator>Wade Warren Stanfield</creator><creator>Zubovics Zoltan</creator><creator>Yang Yun</creator><creator>Toro Andras</creator><creator>Wu Zhipeng</creator><creator>Zeng Qingping</creator><scope>EVB</scope></search><sort><creationdate>20180116</creationdate><title>IRE-1α inhibitors</title><author>Patterson John Bruce ; Wade Warren Stanfield ; Zubovics Zoltan ; Yang Yun ; Toro Andras ; Wu Zhipeng ; Zeng Qingping</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_US9867803B23</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2018</creationdate><topic>CHEMISTRY</topic><topic>HETEROCYCLIC COMPOUNDS</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><toplevel>online_resources</toplevel><creatorcontrib>Patterson John Bruce</creatorcontrib><creatorcontrib>Wade Warren Stanfield</creatorcontrib><creatorcontrib>Zubovics Zoltan</creatorcontrib><creatorcontrib>Yang Yun</creatorcontrib><creatorcontrib>Toro Andras</creatorcontrib><creatorcontrib>Wu Zhipeng</creatorcontrib><creatorcontrib>Zeng Qingping</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Patterson John Bruce</au><au>Wade Warren Stanfield</au><au>Zubovics Zoltan</au><au>Yang Yun</au><au>Toro Andras</au><au>Wu Zhipeng</au><au>Zeng Qingping</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>IRE-1α inhibitors</title><date>2018-01-16</date><risdate>2018</risdate><abstract>Compounds which directly inhibit IRE-1α activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response or with regulated IRE1-dependent decay (RIDD) and can be used as single agents or in combination therapies.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng |
| recordid | cdi_epo_espacenet_US9867803B2 |
| source | esp@cenet |
| subjects | CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES |
| title | IRE-1α inhibitors |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T21%3A45%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=Patterson%20John%20Bruce&rft.date=2018-01-16&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EUS9867803B2%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |